Cosmo PharmaceuticalsN.V. (SIX: COPN, XETRA: C43) is a specialty pharmaceutical company with a focuson gastroenterology and endoscopy. Cosmo develops and manufactures productswhich are distributed globally including Lialda® /Mezavant®, Uceris®/Cortiment® and Aemcolo®/RelaFalk®.
Cosmo has developed GI Genius™, the first device approved by the US Food and Drug Administration (FDA) that uses artificial intelligence to help detect potential signs of colon cancer, Methylene Blue MMX® which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Eleview® which is a medical device to make the removal of colorectal lesions safer and more efficient.
Cosmo’s extensive galenic experience, which led to the development of the proprietary multi-matrix technology MMX®, provides an excellent basis for the development of new and patentable products, manufactured at the Company’s own GMP-approved plant.
In addition, Cosmo holds stakes in other companies as a result of partnerships and spin-offs including shareholdings in Cassiopea (SIX: SKIN), RedHill Biopharma Ltd. (NASDAQ: RDHL), Acacia Pharma Group plc (EURONEXT: ACPH) and PAION AG (Frankfurt Stock Exchange, Prime Standard: PA8)